ALEXION PHARMACEUTICALS, INC.

Lobbying client · Massachusetts · filed 2025 to 2026

Rare Disease Pharmaceutical company.

$360,000 Reported spend

6 Filings counted

1 Firms hired

1 Bills named

Spend is reported income plus in-house expenses across 6 filings. Everything on this page is grouped by the client's LDA id (213126), not by name.

Firms hired 1

FEROX STRATEGIES $360,000 6 filings

Bills named in these filings 1

HR 946
ORPHAN Cures Act

4 filings

Reported by year 2 years

2026 $120,000 2 filings
2025 $240,000 4 filings

Issues lobbied 1

Health Issues 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 6
SENATE 6

Recent filings 6 total

Q2

FEROX STRATEGIES

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $60,000 income · posted Jul 20, 2026

View → Q1

FEROX STRATEGIES

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $60,000 income · posted Apr 17, 2026

View → Q4

FEROX STRATEGIES

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $60,000 income · posted Jan 20, 2026

View → Q3

FEROX STRATEGIES

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $60,000 income · posted Oct 20, 2025

View → Q2

FEROX STRATEGIES

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $60,000 income · posted Jul 18, 2025

View → Q1

FEROX STRATEGIES

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $60,000 income · posted Apr 17, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.